Preoperative Evaluation of Cardiac Patient for Noncardiac surgery

Slides:



Advertisements
Similar presentations
ANESTHESIA FOR A GERIATRIC PATIENT WITH HEART DISEASE
Advertisements

Atrial Fibrillation Cardiovascular ISCEE 26th October 2010.
Acquired Heart Disease
Perioperative Issues Dr John Oyston Dept of Medicine Rounds April 15 th 2008.
Lipid Management in 2015: Risk & Controversies
B. C. Kansupada, MD, HeartCare Assoc. ACC chapter talk 4/28/06.
Stenting Patients Needing Non-Cardiac Surgery
Ryan Hampton January  Risks and benefits of surgery  Timing of surgery  Type of Surgery  Goal is to uncover undiagnosed problems or treat prior.
CARDIAC RISK ASSESSMENT FOR NONCARDIAC SURGERY JOHN HAMATY D.O. SOUTH JERSEY HEART GROUP SJHG.ORG.
Jacobi Ambulatory Care Service Medical Consultation: An Overview Lori A. Lemberg, MD Fall 2012.
Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.
PREOPERATIVE ASSESSMENT OF THE GERIATRIC PATIENT Cheryl Hinners M.D.
Cardiovascular Pre-Operative Evaluation for Non-Cardiac Surgery Jessica Thom PGY-1.
Copyright ©2007 American College of Cardiology Foundation. Restrictions may apply. Fleisher, L. A. et al. J Am Coll Cardiol 2007;50:e159-e242 Cardiac evaluation.
Guidelines for Perioperative Cardiovascular Evaluation for Noncardiac Surgery* A Report of the American College of Cardiology/American Heart AssociationTask.
CABG GUIDELINES SANJAY DRAVID, M.D.. INTRODUCTION ACC/AHA GUIDELINE UPDATE FOR CORONARY ARTERY BYPASS GRAFT SURGERY (JACC 2004; 44: AND CIRCULATION.
Focusing on the Surgical Patient with Cardiac Problems By Kate J. Morse, RN, ACNP-BC, CCRN Nursing2009, March ANCC contact hours Online:
Epidemiology of Noncardiac Surgery Dr. Mohammed Naser.
Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery 2007 ACC/AHA and 2009 ESC GUIDELINES.
Perioperative Cardiovascular Evaluation for Noncardiac Surgery By :Mahmoud M Othman MD, Prof of Anesthesia & SICU, Mansoura faculty of Medicine.
Preoperative assessment
Perioperative Risk Assessment - Can You Get It Right?
Cardiac Arrhythmias in Coronary Heart Disease SIGN 94.
Syncope & serial troponins don’t mix Cost Containment Project June 2015 Alex Raufi PGY2.
Perioperative and Consultative Medicine Pamela J. Pride MD, FHM Medical University of South Carolina 2/7/2012.
Preoperative Cardiac Evaluation Jonathan Hastie January 31, 2006.
1 Covenants of the Medical Home Neighborhood  How Primary Care Physicians and Specialists can “Choose Wisely”
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
1 What is… ? Disparities Among Women in Acute Cardiac Care Frances Canet, MD Cath Conference Thursday, May 26, 2011.
Arthur Stillman, M.D., Ph.D., PI Pamela Woodard, M.D., Study Co-chair Randomized Evaluation of Patients with Stable Angina Comparing Utilization of Diagnostic.
Perioperative Testing
C.H.T Dr.Salarifar 1 Tehran Heart Center Tehran University of Medical Sciences PCI VS CABG M. SALARIFAR, MD.
Perioperative and Consultative Medicine Pamela J. Pride MD, FHM Medical University of South Carolina 2/7/2012.
Current Management of Heart Failure GP clinical update 17 th June 2015 Dr Raj Bilku Consultant Cardiologist Clinical Lead Cardiology QEH.
Indication and contra-indications for cardiac catheterization
Management of Stable Angina SIGN 96
Management of Chronic Stable Angina AIMGP Seminar Series Mirek Otremba 2007.
DR. ZAHOOR 1.  A 50 year old man presents to clinic with a complaint of central chest discomfort of 2 weeks’ duration, occurring after walking for more.
3/99medslides.com1 Guidelines for Perioperative Cardiovascular Evaluation for Noncardiac Surgery ACC/AHA Task Force JACC 1996; 27: Circulation 1996;
Locally Agreed Guidelines May Reduce Inappropriate Preoperative Echocardiography Requests Dr Sheila Carey Anaesthetic SpR Northern Deanery.
Myocardial Ischemia: Concepts in Management Topics in Clinical Medicine February 14, 2007.
Silent Ischemia STABLE CAD
Perioperative and Consultative Medicine Pamela J. Pride MD, FHM Medical University of South Carolina 2/7/2012.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Pre-operative Cardiovascular Evaluation: Guidelines and More Eric A. Brody MD, FACC Medical Director, NA Cardiology and Medical Services Associate Professor.
Pre-operative Assessment of the Surgical Patient
ACC/AHA 2006 guidelines on the management of PAD.
Preoperative Cardiac Evaluation
Multivessel Coronary Artery Disease
Patient Selection & Risk Stratification Soltani GH, MD.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Dr. Alireza Pournajafian – Assistant Professor of Anesthesia
Cardio-Pulmonary Pre Operative Risk Assessment Andy Shakespeare MD PGY2 Baylor Scott and White IM
Oncology Institute of Vojvodina Department of anaesthesiology and intensive care Institutski put 4, Sremska Kamenica, SERBIA
Date of download: 6/23/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS.
Segment 1 Perioperative Risk Assessment. Need Advice – How Low is Low Dear Consult Sages ; I need your help and guidance to provide better service to.
Faramarz Amiri MD IUMS.  Severe carotid disease (defined as >80%) 8–12%  Severe carotid disease (>70%) in those with three vessel or left main coronary.
Indication Contraindication Preparation
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 Appropriate.
Choosing Wisely: Cardiology Jeffrey Ziffra D.O. Mercy Medical Center – North Iowa 10/14/2016.
© free-ppt-templates.com 2017 AHA/ACC Focused Update of Valvular Heart Disease Guideline of 2014 DR. OMAR SHAHID TR CARDIOLOGY SZH.
Multi Modality Approach to Diagnosis of Ischemia in Post CABG Cases
CORONARY ARTERY DISEASE
preoperative evaluation
Section III: Neurohormonal strategies in heart failure
Peter K. Smith, MD  The Journal of Thoracic and Cardiovascular Surgery 
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Lee A. Fleisher et al. JACC 2014;64:e77-e137
Presentation transcript:

Preoperative Evaluation of Cardiac Patient for Noncardiac surgery Dr Balaji Asegaonkar MD,DNB (Anaesthesia) Consultant cardiac anaesthesiologist Ozone Anaesthesia Group, Aurangabad.

CASE 1 65 YR MALE ,HT SINCE 5 YRS,DM SINCE 5 YRS ON INSULIN AND IHD ANGIOPLASTY DONE 10 MONTHS BACK WITH DRUG ELUTING STENTS ON DUAL ANTIPLATELATE AGENTS TO BE POSTED FOR TURP

CASE 2 70 YR MALE ,HYPERTENSIVE, DIABETIC & SEVERE OSTEOARTHRITIS. SMOKER FOR LAST 30 YRS. TO BE POSTED FOR TKR

CASE 3 80 YRS MALE, HT, IHD- POST PLASTY, POOR EFFORT TOLERANCE TO BE POSTED FOR CATARACT

Let’s face it… The surgical population is older, sicker, on more medications, and having more & more cardiac interventions. There is a subset of your patients for whom the patient, the surgeon, or you may have questions about cardiovascular risk.

So what do you do? Guess?…Argue?…Worry?…Refer everyone cardiological investigations OR do a thorough, focused exam. Followed by the individualized application of some authoritative guidelines… …for evaluation, risk stratification, and management… …and refer, delay, or cancel only when appropriate.

Authoritative guidelines…..? Evidence based medicine. Based on research findings, expert opinion, and consensus . Cardiovascular authority, like American College of Cardiology/American Heart Association. Anaesthesiology authority, like ASA. I am not a cardiologist, nor do I play one on TV. The point is to learn as much as possible, act responsibly based on your own knowledge and the knowledge of experts, and get assistance when you need it.

Objectives: How to approach cardiac Patients. Risk stratification. Modification of level of care. Discuss standard recommendation.

focused approach……… We are not cardiologists, We simply need to recognize when a cardiac condition might affect the patient’s response to anaesthesia, and what to do about it. We need to be: Thorough enough to find all significant problems (sensitivity). Focused enough to consider only significant problems (specificity).

…and Stepwise Approach? Thorough, focused cardiac evaluation ACC/AHA Guidelines for Perioperative Cardiovascular Evaluation for Noncardiac Surgery (2007). Indicated cardiac testing and consultation. Optimization of cardiovascular function in relation to the demands of the surgery and the anaesthesia.

The courage is knowledge of how to fear what ought to be feared & how not to fear what ought not to be feared.

Applying Classification of Recommendations and Level of Evidence Class I Benefit >>> Risk Procedure/ Treatment SHOULD be performed/ administered Class IIa Benefit >> Risk Additional studies with focused objectives needed IT IS REASONABLE to perform procedure/administer treatment Class IIb Benefit ≥ Risk Additional studies with broad objectives needed; Additional registry data would be helpful Procedure/Treatment MAY BE CONSIDERED Class III Risk ≥ Benefit No additional studies needed Procedure/Treatment should NOT be performed/administered SINCE IT IS NOT HELPFUL AND MAY BE HARMFUL Level of Evidence: Level A: Data derived from multiple randomized clinical trials or meta-analyses Multiple populations evaluated Level B: Data derived from a single randomized trial or nonrandomized studies Limited populations evaluated Level C: Only consensus of experts opinion, case studies, or standard of care Very limited populations evaluated

So, let’s start with … The Preop portion of the ACC/AHA Guidelines, which is based on your history and physical, plus indicated tests.

Guidelines : Stepwise approach Need for surgery:Emergent vs Urgent/Elective. Clinical Risk Predictors: (Major, Intermediate, Minor). Functional capacity (Exercise tolerance).

ACC/AHA Guidelines: Preop Surgical Risk Predictors: (High, Intermediate, Low) Recent coronary revascularization or Evaluation.

Major Clinical Risk Predictors Unstable Coronary Syndromes: Recent MI (> 7 and < 30 days). Unstable angina (Canadian Class III-IV). Decompensated CHF. Significant Dysrhythmias. High-grade AV block. Symptomatic ventricular dysrhythmias. Supraventricular dysrhythmias with uncontrolled ventricular rate. Severe Valve Disease.

Intermediate Clinical Risk Predictors Mild angina (Canadian Class I - II). Prior MI by history or pathological Q waves. Compensated or prior CHF. Diabetes, especially IDDM. Renal Insufficiency (creatinine > 2mg%).

Minor Clinical Risk Predictors Advanced age. Abnormal ECG (LVH, LBBB, ST-T abnl). Rhythm other than sinus (e.g. a-fib). Low functional capacity (< 4 METs). Hx CVA. Uncontrolled HTN (>180 / >110). So, at some point someone is going to ask, “What’s Canadian Class Angina?”

Cardiac Functional Classification: Canadian Cardiovascular Society No angina with ordinary physical activity . Angina with strenuous exertion. II. Slight limitation of ordinary activity. III. Marked limitation of ordinary activity. IV. Inability to carry on any physical activity without discomfort. Angina may be present at rest.

Functional Capacity = Exercise Tolerance Major clinical risk predictors are sufficient alone to trigger further testing or intervention before pt posted for Sx. Intermediate and minor clinical risk predictors are subject to a second step: Evaluation of cardiovascular functional capacity, i.e., exercise tolerance.

Exercise Tolerance Angina or anginal equivalents (DOE, palpitations, fatigue)= Ischemic threshold. Point where metabolic demand > supply Metabolic equivalent (MET): 1 MET = resting O2 consumption(VO2) = 3.5mL/kg/min Functional capacity in METs: Poor: < 4 Mod: 4-7: > 4 is the “tipping point”. Good: 7-10. Excellent: > 10.

Exercise Tolerance in METs 1 MET: Eat, dress, use the toilet. 2 METs: Household ambulation. 3 METs: Light housework. Walk level ground 2-3 MPH. 4 METs: Walk up one flight stairs. Walk level ground 4 MPH. 4-10 METs: Run short distance. Scrub floors, move furniture. Moderate sports. >10 METs: Strenuous sports.

Surgical Risk Predictors High (> 5% Cardiac Death/MI). Emergent major operation, espec. in elderly, Aortic and other major vascular Sx Peripheral vascular,Prolonged procedure. Intermediate (< 5%). Carotid endarterectomy, Head & neck Intraperitoneal, Intrathoracic, Prostate, Ortho Low (< 1%). Endoscopic, Superficial, Cataract, Breast

Procedure Details : Angioplasty Time since procedure. Which artery. Present medication. Symptoms benefits. Baseline ECG. Which stents.

DRUG ELUTING STENT ANTICACER DRUGS COATED. SLOW RELEASE TILL 6 TO 8 MONTH. NO ENDOTHELIAZATION. LEAST CHANCE OF INSTENT THROMBOSIS ANTIPLATELETS

Post plasty :Noncardiac surgery

Treatment for patients requiring PCI who need subsequent surgery

Procedure Details : CABG Time since procedure. Which arteries grafted & Type of conduit. Present medication. Symptoms benefits. Baseline ECG

Recommended stepwise approach How urgent noncardiac surgery is ? p/o risk stratification & assessment done. All these are Gr V cases.

Step 2 Has Pt undergone coronary revascularisation in past 5 yrs ? If yes & Pt has no s/s of cardiac problem – further detail cardiac testing not required.

Step 3 If Pt has any coronary evaluation in past 2 yrs – revealing no significant CAD ,if there is no aggravations of s/s –no further testing is needed.

Step 4 Does Pt have any major clinical predictors ? Delay noncardiac surgery until problem has identified & treated.

Step 5 If Pt have intermediate clinical predictors. Consider functional capacity & surgery specific risks. Decide accordingly weather further testing needed or not.

Step 6 Pt with intermediate predictor & mod to excellent functional capacity can undergo intermediate Sx. Pt with 2 or more intermediate predictor & poor functional capacity OR mod functional capacity but high risk Sx – further testing & evaluation needed.

Step 7 Noncardiac Sx safe in Pt with minor clinical predictor & mod to excellent functional capacity. Additional testing must for Pt with no clinical predictors but poor functional capacity & who are facing high risk Sx.

CASE 1 65 YR MALE ,HT SINCE 5 YRS,DM SINCE 5 YRS ON INSULIN AND IHD ANGIOPLASTY DONE 10 MONTHS BACK WITH DRUG ELUTING STENTS TO BE POSTED FOR TURP

CASE 2 70 YR FEMALE ,HYPERTENSIVE & SEVERE OSTEOARTHRITIS. CABG DONE 2 YRS BACK ON ANTIPLATE, ANTI HT & STATINS TO BE POSTED FOR TKR

CASE 3 80 YRS MALE, HT, IHD- POST PLASTY, POOR EFFORT TOLERANCE TO BE POSTED FOR CATARACT

Thanks....!

Step 8 In documented CAD , if risk of coronary interventions or CABG exceeds proposed noncardiac Sx & if such Sx improves long term prognosis of Pt – noncardiac Sx should be done.

Summary from ACC / AHA Perioperative evaluation and mgmt of high-risk cardiac patients for noncardiac surgery requires careful teamwork and communication between patient, surgeon, anesthesiologist, physian or cardiologist. Indications for cardiac testing and treatments are the same as in the non-operative setting, and should clearly affect patient management. Factors include the urgency of surgery, patient-specific risk factors, and surgery-specific considerations.

Summary For many patients, noncardiac surgery represents their first opportunity for assessment of short- and long-term cardiac risk. The consultant best serves the patient by making recommendations aimed at lowering the immediate perioperative cardiac risk, as well as assessing the need for postoperative risk stratification and interventions directed to modify cardic risk factors. Future research should be directed at determining the value of routine prophylactic medical therapy vs. more extensive diagnostic testing and interventions.

Proposed Approach to the Management of Patients with Previous PCI Who Require Noncardiac Surgery Balloon Bare-metal Drug-eluting angioplasty stent stent <365 days >30- 45 days <30- 45 days >365 days Time since PCI <14 days >14 days Delay for elective or Proceed to the Delay for elective or Proceed to the nonurgent surgery operation room nonurgent surgery operating room with aspirin with aspirin PCI, percutaneous coronary intervention

Proposed Treatment for Patients Requiring PCI Who Need Subsequent Surgery Acute MI, H risk ACS, or H risk cardiac anatomy Stent & continue dual antiplatelet therapy Bleeding risk of surgery low Not low Timing of surgery 14-29 days 30-365 days >365 days Bare-metal stent Balloon angioplasty Drug-eluting stent

Recommendations for Perioperative Beta-Blocker Therapy Surgery No Clinical Risk Factors CAD or High Risk (1 or more clinical risk factors) Patients Currently Taking Beta Blockers Vascular Class llb, Level of Evidence: B Class lla, Level of Evidence: B Class 1, Level of Evidence: C Intermediate risk … Low risk

Recommendations for Statin Therapy For patients currently taking statins and scheduled for noncardiac surgery, statins should be continued. For patients undergoing vascular surgery with or without clinical risk factors, statin use is reasonable. For patients with at least 1 clinical risk factor who are undergoing intermediate-risk procedures, statins may be considered. I IIa IIb III B

Happy Anaesthesia Day

Aims on evaluation Delay case for treatment of unstable symptoms. Modification of intraoperative or postoperative (e.g. ICU) monitoring.

Aims on evaluation Modification of perioperative medical therapy. Coronary or valve procedure before noncardiac surgery. Modification of location of care

Rest ECG: Indications Class I:Recent angina with intermed-high risk clinical predictors for intermed-high risk procedure. Class IIa: Asymptomatic diabetics. Class IIb: Prior coronary revascularization or cardiac hospital admission. Asymptomatic males > 45 or females > 55 with 2 CAD risk factors. Class III: Asymptomatic pts. For low-risk procedures

Rest ECG: Significant Findings Path.Q waves (> 0.4s wide, or > 25% of R, in 2 contiguous leads): Size and extent predict LVEF, long term mortality. Horizontal or downsloping ST depression > 0.5mm, LVH with strain pattern (ST depression + TWI in I, II, III, AVL or AVF, V5, V6), LBBB with CAD predict increased perioperative risk and long term mortality. Significant dysrhythmias: High-grade AV block, symptomatic ventricular dysrhythmias, supraventricular dysrhythmias with uncontrolled rate.

Echocardiogram: Indications Asymptomatic murmurs : Class I: Diastolic, continuous, holosystolic, mid & late systolic, III/VI murmurs. Class IIa: Murmur assoc with abnl cardiac palpation or auscultation, abnl ECG or CXR. Class III: II/VI midsystolic innocent murmur. Dx of “silent” AR or MR without murmur, to recommend endocarditis prophylaxis.

Echocardiogram: Indications Symptomatic murmur: Class I: S/S of CHF, MI, syncope, infective endocarditis, thromboembolism Class IIA: S/S possibly non-cardiac. Class III: S/S non-cardiac dz with midsystolic “innocent” murmur

Stress Testing: ECG or Echo Normal rest ECG → ECG stress, Abnl ECG → Echo Class I: Dx of intermediate probability CAD, Prognosis of CAD or s/p ACS, Eval of med tx. Proof of ischemia before revascularization. Class IIa: Evaluate exercise tolerance in unreliable historian. Class IIb: Dx of high or low probability CAD, Resting ST depression < 1mm, On digoxin, LVH by ECG, Dx of restenosis in high-risk asymptomatic . Class III: Resting pre-excitation or ST depression > 1mm, Routine screening. 28

Recommendations for CAG in Preop Evaluation Class I: Patients With Suspected or Known CAD Evidence for high risk of adverse outcome based on noninvasive test results. Angina unresponsive to adequate medical therapy. Unstable angina, particularly when facing intermediate-risk* or high-risk* noncardiac surgery. Equivocal noninvasive test results in patients at high clinical risk undergoing high-risk* surgery. Class IIa Multiple markers of intermediate clinical risk and planned vascular surgery (noninvasive testing should be considered first). Moderate to large ischemia on noninvasive testing but without high-risk features and lower left ventricular ejection fraction. Nondiagnostic noninvasive test results in patients at intermediate clinical risk undergoing high-risk* noncardiac surgery. Urgent noncardiac surgery while convalescing from acute MI.

Recommendations for CAG in Preop Evaluation Class IIb Perioperative MI. Medically stabilized class III or IV angina and planned low-risk or minor* surgery. Class III Low-risk* noncardiac surgery with known CAD and no high-risk results on noninvasive testing. Asymptomatic after coronary revascularization with excellent exercise capacity (greater than or equal to 7 METs). Mild stable angina with good left ventricular function and no high-risk noninvasive test results. Noncandidate for coronary revascularization owing to concomitant medical illness, severe left ventricular dysfunction (e.g., left ventricular ejection fraction less than 0.20), or refusal to consider revascularization. Candidate for liver, lung, or renal transplant less than 40 years old, as part of evaluation for transplantation, unless noninvasive testing reveals high risk for adverse outcome.